Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab + ipilimumab N01 + cetuximab + dabrafenib in MSS BRAF V600E-mutant metastatic colorectal cancer
ChiCTR2600133230Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, ipilimumab, cetuximab and dabrafenib + trametinib in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumabcetuximabdabrafenib + trametinib
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2600133230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133230.